Novartis Acquires Chinese Vaccine Company - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis Acquires Chinese Vaccine Company


ePT--the Electronic Newsletter of Pharmaceutical Technology

Novartis acquired a majority stake in Zhejiang Tianyuan Bio-Pharmaceutical, one of the largest privately held vaccine companies in China. The acquisition gives Novartis an expanded presence in the Chinese vaccine market and will facilitate the introduction of Novartis's vaccines into the country.

"This agreement combines the strength of our vaccines research and development strategy and pipeline with Tianyuan's deep knowledge of the vaccines market in China," said Andrin Oswald, Head of Novartis Vaccines and Diagnostics, in a statement.

According to the statement, Novartis will collaborate with Tianyuan to strengthen its vaccine portfolio and pipeline, as well as align production processes and quality standards. Novartis also added that it plans to explore new vaccine developments to address unmet medical needs in China.

"We have already identified several joint development programs that could be implemented in China over the next 10 years, with the potential of launching key products responding to unmet medical needs in the mid-term," said Ding Xiaohang, Founder, Chairman and CEO of Tianyuan, in the statement.

In related news, Novartis will eliminate more than 500 positions at its Horsham, United Kingdom site. The full story is available at BBC news.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here